Kenneth Lundstrom
Research Subjects
Kenneth Lundstrom has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
Teni Boulikas
Regulon Inc. Mountain View, CA, USA
1 shared publication
Latest Publications
- Open Access
- 1 October 2003
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 2 (5) , 471-485
Viral and Non-viral Vectors in Gene Therapy: Technology Development and Clinical Trials
Gene therapy as part of modern molecular medicine holds great promise for the treatment of both acute and chronic diseases and has the potential to bring a revolutionary era to cancer treatment. Gene therapy has been named the medicine of the future. For the past 10 years various viral and non-viral vectors have been engineered for improved gene and drug delivery. Although various diseases have been targeted, cancer therapy has been addressed to a large extent because of the straight forward approach. Delivery of toxic or immunostimulatory genes by viral and non-viral vectors has been investigated and encouraging results have been obtained in animal models. A large number of clinical trials have been conducted with some highly promising outcome. We propose that combinations of viruses with lipo-somes or polymers will solve the problem of systemic viral delivery and tumor targeting, bringing a revolution in molecular medicine and in applications of gene therapy in humans.
- 1 October 2003
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 2 (5) , 471-485
Open AccessViral and Non-viral Vectors in Gene Therapy: Technology Development and Clinical Trials
Gene therapy as part of modern molecular medicine holds great promise for the treatment of both acute and chronic diseases and has the potential to bring a revolutionary era to cancer treatment. Gene therapy has been named the medicine of the future. For the past 10 years various viral and non-viral vectors have been engineered for improved gene and drug delivery. Although various diseases have been targeted, cancer therapy has been addressed to a large extent because of the straight forward approach. Delivery of toxic or immunostimulatory genes by viral and non-viral vectors has been investigated and encouraging results have been obtained in animal models. A large number of clinical trials have been conducted with some highly promising outcome. We propose that combinations of viruses with lipo-somes or polymers will solve the problem of systemic viral delivery and tumor targeting, bringing a revolution in molecular medicine and in applications of gene therapy in humans.